Image Credit: Bankim Desai / Shutterstock
Ashwagandha boosts memory and mood in clinical trial
Study: Acute and Repeated Ashwagandha Supplementation Improves Markers of Cognitive Function and Mood.
In a recent study published in the journal Nutrients, researchers in the United States evaluated the impact of acute and repeated Ashwagandha (Withania somnifera) (ASH) supplementation on cognitive function and mood markers.
Background
Due to its antioxidant, endocrine-influencing, and immunomodulatory properties, ASH has been used for over 3,000 years in Ayurvedic medicine to manage stress, anxiety, and inflammation. Known to reduce cognitive decline related to inflammation and neurodegeneration, it is bioavailable and crosses the blood-brain barrier, making it therapeutic for conditions like type 2 diabetes mellitus, mild cognitive impairment (MCI), and neurodegenerative diseases. While studies show cognitive benefits in both clinical and healthy populations, such as improved memory and reduced stress markers, further research is needed to fully understand its long-term effects and mechanisms, especially in diverse populations.
About the study
In the present double-blind, placebo-controlled clinical trial, participants aged 18 to 60 were recruited through various channels and screened for eligibility. Sixty individuals were enrolled and randomly assigned to either the placebo (PLA) group or the ASH group, with one participant excluded for non-compliance. The study was registered with the International Standard Randomised Controlled Trial Number (ISRCTN) and approved by the Human Research Protection Program Review Board.
Participants attended a familiarization and two testing sessions, completing cognitive function tests (COMPASS), Profile of Mood States (POMS) questionnaires, and blood sample collections. Pre-supplementation assessments were conducted, followed by random assignment to placebo (225 mg of Gum Arabic) or liposomal ASH (225 mg of NooGandha®), with post-supplementation testing an hour later. Daily supplementation continued for 30 days, with final assessments mirroring initial protocols.
Cognitive function was evaluated using COMPASS software, and mood states were assessed via POMS. Blood samples were analyzed for health markers, and side effect perceptions were recorded. Statistical analysis using SPSS software included repeated measures General Linear Model (GLM) analyses and chi-squared tests for side effect differences, with clinical significance determined by mean changes from baseline and effect sizes assessed through partial Eta squared values.